{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jen WY"],"funding":["NCI NIH HHS","NIH HHS"],"pagination":["2451-2461"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12490727"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["207(6)"],"pubmed_abstract":["MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was associated with overall survival (OS). We included 152 adult patients with newly diagnosed MECOM-r and classified blast percentage into <20% or ≥20% and MECOM-r partner into classic (GATA2::MECOM) or variant (others). Thirty-one per cent had <20% blasts, with 69% having ≥20%; 57% had classic and 43% variant MECOM-r. Treatment was with intensive chemotherapy (IC) in 41% and low-intensity therapy (LIT) in 59%. Composite complete remission rates were similar between IC (50%) and LIT (48%, p = 0.99). The median OS was 17 months (95% confidence interval [CI], 12-not estimable [NE]) for <20% blasts, "],"journal":["British journal of haematology"],"pubmed_title":["MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia."],"pmcid":["PMC12490727"],"funding_grant_id":["P30 CA016672","P50 CA100632","CA100632"],"pubmed_authors":["Sasaki K","Issa GC","Pierce S","Montalban-Bravo G","Tang G","Garcia-Manero G","Kantarjian HM","Kugler E","Bataller A","Loghavi S","Daver NG","Kadia TM","Toruner GA","Jen WY","Bazinet A","Popat U","Short NJ","Jabbour E","Bhalla K","DiNardo CD","Pemmaraju N","Croden J","Bouligny IM","Borthakur G","Ravandi F"],"additional_accession":[]},"is_claimable":false,"name":"MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.","description":"MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was associated with overall survival (OS). We included 152 adult patients with newly diagnosed MECOM-r and classified blast percentage into <20% or ≥20% and MECOM-r partner into classic (GATA2::MECOM) or variant (others). Thirty-one per cent had <20% blasts, with 69% having ≥20%; 57% had classic and 43% variant MECOM-r. Treatment was with intensive chemotherapy (IC) in 41% and low-intensity therapy (LIT) in 59%. Composite complete remission rates were similar between IC (50%) and LIT (48%, p = 0.99). The median OS was 17 months (95% confidence interval [CI], 12-not estimable [NE]) for <20% blasts, ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T13:36:26.558Z","creation":"2026-05-31T03:07:50.884Z"},"accession":"S-EPMC12490727","cross_references":{"pubmed":["40983567"],"doi":["10.1111/bjh.70171"]}}